Heron Therapeutics ( HRTX ) Reports Q2 Loss, Misses Revenue Estimates
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -100.00% and -1.89%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Heron ( HRTX ) Q2 Acute Care Jumps 56%
Heron Therapeutics ( NASDAQ:HRTX ) , a biopharmaceutical company focused on acute care and oncology drugs, released its second quarter 2025 results on August 8, 2025. The standout news was a 55.5% jump in Acute Care segment revenue, offset by another GAAP revenue shortfall versus analyst ...
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
This Ryder System Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Etoro Group ( NASDAQ:ETOR ) , Antalpha Platform Holding ( NASDAQ:ANTA )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. HC Wainwright & Co. analyst Brandon Folkes initiated coverage on Heron Therapeutics, Inc.
Heron Therapeutics ( HRTX ) Q1 Earnings and Revenues Top Estimates
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 200% and 4.93%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer - CytoDyn ( OTC:CYDY )
VANCOUVER, Washington, May 06, 2025 ( GLOBE NEWSWIRE ) -- CytoDyn Inc. CYDY ( "CytoDyn" or the "Company" ) , a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that Robert E.
MTD Q1 Earnings Top Estimates, Sales Decline Y/Y, Shares Rise
Mettler-Toledo International's Q1 results reflect growth in the Laboratory business, a decline in Industrial, and continued weakness in the Food Retail segment.
Akebia Therapeutics ( AKBA ) Expected to Beat Earnings Estimates: Should You Buy?
Akebia Therapeutics (AKBA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Heron Therapeutics ( HRTX ) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Heron Therapeutics (HRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics
Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics are part of the Zacks Industry Outlook article.
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms
Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one's portfolio.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Best Momentum Stocks to Buy for April 22nd
DPMLF, HRTX and FOX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 22, 2025.
Are Medical Stocks Lagging Encompass Health ( EHC ) This Year?
Here is how Encompass Health (EHC) and Heron Therapeutics (HRTX) have performed compared to their sector so far this year.
New Strong Buy Stocks for April 22nd
DPMLF, PAM, MTAL, HRTX and BALY have been added to the Zacks Rank #1 (Strong Buy) List on April 22, 2025.
Why Marvell Technology Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - CN Energy Group ( NASDAQ:CNEY ) , Bolt Projects Holdings ( NASDAQ:BSLK )
Shares of Marvell Technology, Inc. MRVL rose sharply in today's pre-market trading after the company reported better-than-expected third-quarter financial results and issued fourth-quarter guidance above estimates.
Starbucks To $77? Here Are 10 Top Analyst Forecasts For Wednesday - Starbucks ( NASDAQ:SBUX )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler boosted the price target for Shopify Inc. SHOP from $67 to $94.
Heron Therapeutics ( HRTX ) Reports Q3 Loss, Misses Revenue Estimates
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 0% and 9.86%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Unveiling Heron Therapeutics ( HRTX ) Q3 Outlook: Wall Street Estimates for Key Metrics
Evaluate the expected performance of Heron Therapeutics (HRTX) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Journey Medical ( DERM ) Soars 7.3%: Is Further Upside Left in the Stock?
Journey Medical (DERM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Cancer Supportive Care Product Market is Set to Surge at 6.9% CAGR, to Reach US$ 68.93 Billion by 2034 | Fact.MR
Rockville, MD, Sept. 24, 2024 ( GLOBE NEWSWIRE ) -- In its new study, Fact.MR states that the global cancer supportive care product market is estimated to reach a value of US$ 35.47 billion in 2024 and thereafter advance at a CAGR of 6.9% from 2024 to 2034.
Chemotherapy Induced Nausea and Vomiting Treatment Market is Set to Reach US$ 12,688.0 Million by 2034 | Fact.MR
Rockville, MD, Sept. 17, 2024 ( GLOBE NEWSWIRE ) -- According to Fact.MR, a market research and competitive intelligence provider, the global chemotherapy induced nausea and vomiting treatment market is estimated to reach a valuation of US$ 6,823.0 million in 2024 and is expected to grow at a ...
Heron Therapeutics ( HRTX ) Reports Q2 Loss, Tops Revenue Estimates
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -50% and 1.91%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Kazia Therapeutics ( KZIA ) Soars 490% in a Week: Here's Why
Kazia (KZIA) surges after positive data from a phase II/III study on its lead pipeline drug in patients with glioblastoma. Based on this data, it plans to seek an accelerated nod from the FDA.
Heron Therapeutics ( HRTX ) Upgraded to Strong Buy: Here's What You Should Know
Heron Therapeutics (HRTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
United Therapeutics ( UTHR ) Completes Enrolment in IPF Study
United Therapeutics' (UTHR) late-stage study is evaluating Tyvaso inhalation solution in IPF patients living outside the United States and Canada.
New Strong Buy Stocks for July 11th
SKIL, INKT, MLCO, GTLB, and HRTX have been added to the Zacks Rank #1 (Strong Buy) List on July 11, 2024.
Indivior ( INDV ) Down on Dropping Schizophrenia Drug, Cuts '24 View
Indivior (INDV) slashes financial guidance for 2024, primarily to reflect adverse sales conditions of its top-selling opioid drug. It will discontinue the sales of its schizophrenia drug.
Merck ( MRK ) Gets Exclusive Rights to Opevesostat From Partner
Merck (MRK) exercises the option that will convert the collaboration deal with partner Orion for prostate cancer candidate opevesostat into a license agreement.
FDA Rejects Rocket's ( RCKT ) Gene Therapy BLA for Rare Disease
Per the FDA, Rocket (RCKT) needs to submit additional manufacturing information on Kresladi gene therapy to secure approval for severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.
FDA Expands AbbVie's ( ABBV ) Epkinly Label in Follicular Lymphoma
Following the label expansion, AbbVie's (ABBV) Epkinly is the first bispecific antibody approved to treat relapsed/refractory (R/R) follicular lymphoma and R/R diffuse large B-cell lymphoma.
AstraZeneca's ( AZN ) Imfinzi Meets Study Goal in Bladder Cancer
Data from a late-stage study shows that treatment with AstraZeneca's (AZN) Imfinzi plus chemotherapy before and after bladder removal surgery improves survival in patients.
Ionis Pharmaceuticals ( IONS ) Soars 6.8%: Is Further Upside Left in the Stock?
Ionis Pharmaceuticals (IONS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
FDA Expands Argenx's Vyvgart Label to Treat Rare Disorder - Arcutis Biotherapeutics ( NASDAQ:ARQT ) , argenx ( NASDAQ:ARGX )
Shares of Argenx ARGX rose nearly 4% on Friday after management announced that the FDA approved its subcutaneously administered Vyvgart Hytrulo ( efgartigimod ) for a second indication - chronic inflammatory demyelinating polyneuropathy ( CIDP ) .
FDA Expands argenx's ( ARGX ) Vyvgart Label to Treat Rare Disorder
Per argenx (ARGX), the label expansion to Vyvgart Hytrulo makes it the first FDA-approved medication with a novel mechanism of action to treat chronic inflammatory demyelinating polyneuropathy.
OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies
Two late-stage studies, which evaluated Ovid Therapeutics' (OVID) experimental drug for two forms of epilepsy, fail to meet their primary endpoints.
Avidity Up 33% on Rare Muscle Disease Study Results - Arcutis Biotherapeutics ( NASDAQ:ARQT ) , Heron Therapeutics ( NASDAQ:HRTX )
Avidity Biosciences RNA announced encouraging initial data from the phase I/II FORTITUDE study evaluating two doses of delpacibart braxlosiran ( del-brax, or formerly AOC 1020 ) in facioscapulohumeral muscular dystrophy ( FSHD ) , a rare genetic disease of the muscles.
Avidity ( RNA ) Up 33% on Rare Muscle Disease Study Results
Initial data from an early-stage study shows that treatment with Avidity's (RNA) experimental therapy could address the underlying cause of a rare muscle-weakening condition.
FDA Expands AstraZeneca's ( AZN ) Farxiga Label in Pediatric T2D
Following the label expansion, AstraZeneca's (AZN) Farxiga is now approved to improve glycemic control in patients aged 10 years and older with T2D. It was previously approved for such use in adults.
Connect Biopharma Announces New Leadership and Chair of the Board of Directors
SAN DIEGO, CA and TAICANG, China, June 12, 2024 ( GLOBE NEWSWIRE ) -- Connect Biopharma Holdings Limited ( Nasdaq: CNTB ) ( Connect or the Company ) , a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory ...
Connect Biopharma Announces New Leadership and Chair of the Board of Directors - Connect Biopharma Hldgs ( NASDAQ:CNTB ) , GRI Bio ( NASDAQ:GRI )
Industry leader Barry Quart, Pharm.D. appointed as Chief Executive Officer succeeding Zheng Wei, Ph.D., who will remain on the Board of Directors and serve as an advisor to assist with the transition Experienced life science executive David Szekeres appointed as President Kleanthis G.
Summit ( SMMT ) Stock Surges 57% in the Past Month: Here's Why
Summit Therapeutics (SMMT) surges after data from a late-stage study shows that its experimental antibody beat Merck's Keytruda in a head-to-head setting in treating certain patients with lung cancer.
Viridian ( VRDN ) Up 10% on Clinical Updates for Eye Disease Drug
Viridian (VRDN) intends to initiate two late-stage studies on its experimental thyroid eye disease drug this August. Top-line data from both studies are expected in ...
Amgen's ( AMGN ) Uplizna Meets Study Goal for Rare Disease
Data from a late-stage study shows that treatment with Amgen's (AMGN) Uplizna achieves a statistically significant reduction in the risk of flares in patients with IgG4-RD, a rare disease.
Eli Lilly ( LLY ) Veteran Anat Ashkenazi to Join Alphabet as CFO
Eli Lilly (LLY) CFO Anat Ashkenazi joins Google's parent company Alphabet as CFO and senior vice president, effective from ...
Here's Why You Should Consider Buying Bioventus ( BVS ) Stock
Here, we discuss some reasons why buying Bioventus (BVS) stock now may turn out to be a prudent move.
Agios ( AGIO ) Up 21% on Upbeat Data From 2nd Thalassemia Study
Data from a late-stage study shows that transfusion-dependent thalassemia patients who received Agios' (AGIO) Pyrukynd demonstrated a statistically significant reduction in transfusion burden.
Biogen ( BIIB ) Gets EU Approval for Rare Disease Drug Qalsody
Biogen's (BIIB) Qalsody is the first therapy approved to treat a rare genetic form of ALS in Europe ...
J&J's ( JNJ ) Oral Pill Improves Depression & Insomnia Symptoms
Data from a late-stage study shows that treatment with J&J's (JNJ) experimental drug met all study endpoints in depression patients with insomnia symptoms.
